Log In
Print
BCIQ
Print
Print this Print this
 

Nuplazid, pimavanserin (formerly ACP-103)

Also known as: pimavanserin tartrate

  Manage Alerts
Collapse Summary General Information
Company Acadia Pharmaceuticals Inc.
DescriptionSmall molecule serotonin (5-HT2A) receptor inverse agonist
Molecular Target Serotonin (5-HT2A) receptor
Mechanism of ActionSerotonin (5-HT2A) receptor inverse agonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$395.0M

$30.0M

$365.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today